What are fasting plasma glucose (FPG) and impaired fasting glucose (IFG)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Definitions of FPG and IFG

Fasting Plasma Glucose (FPG) is a blood glucose measurement taken after at least 8 hours of no caloric intake, while Impaired Fasting Glucose (IFG) is a prediabetic state defined by FPG levels between 100-125 mg/dL (5.6-6.9 mmol/L) according to American Diabetes Association criteria, or 110-125 mg/dL (6.1-6.9 mmol/L) according to World Health Organization criteria. 1

Fasting Plasma Glucose (FPG)

FPG represents a standardized measurement of blood glucose concentration obtained from venous plasma after a minimum 8-hour fast (no caloric intake). 2, 1 This test reflects the body's ability to maintain adequate basal insulin secretion combined with sufficient hepatic insulin sensitivity to control hepatic glucose output. 3

Key technical specifications:

  • Requires venous plasma sample (standardized measurement)
  • Fasting defined as 8-14 hours without caloric intake
  • Should be performed in the morning
  • Measurements from whole blood are approximately 0.5 mmol/L (9 mg/dL) lower than plasma values 3

Impaired Fasting Glucose (IFG)

IFG represents an intermediate category of glucose metabolism—a prediabetic state where glucose levels are elevated above normal but below the diagnostic threshold for diabetes. 4, 1

Diagnostic criteria differ between organizations:

  • American Diabetes Association (ADA): FPG 100-125 mg/dL (5.6-6.9 mmol/L) 2, 5, 1
  • World Health Organization (WHO): FPG 110-125 mg/dL (6.1-6.9 mmol/L) 3, 6

This discrepancy exists because the ADA lowered the threshold from 6.1 to 5.6 mmol/L in 2003 to improve sensitivity for detecting individuals at risk of progression to diabetes. 3 The WHO retained the original 6.1 mmol/L cutoff.

Clinical Significance

IFG is not merely a laboratory finding but a risk state for:

  • Future development of type 2 diabetes
  • Cardiovascular disease
  • Metabolic syndrome components (obesity, dyslipidemia, hypertension) 2, 4

IFG reflects the natural history of progression from normal glucose metabolism to type 2 diabetes. 3 Individuals with IFG often oscillate between different glycemic states, as expected when a continuous variable (plasma glucose) is dichotomized into categories. 3

Important Distinctions

IFG differs from Impaired Glucose Tolerance (IGT):

  • IFG is diagnosed by fasting glucose measurement alone
  • IGT requires a 2-hour oral glucose tolerance test (OGTT) showing 2-hour plasma glucose 140-199 mg/dL (7.8-11.0 mmol/L) 2, 3, 1
  • An individual can have isolated IFG, isolated IGT, or both conditions simultaneously
  • These conditions identify partially overlapping but distinct populations at risk for diabetes 3

Critical caveat: A normal FPG does not exclude IGT or even diabetes—approximately 30% of individuals with diabetes would be missed using FPG alone compared to OGTT. 3 The OGTT remains more sensitive for detecting glucose intolerance, though FPG is more convenient and reproducible for clinical practice. 2, 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.